US EditionPublished • loading... • Updated
Pfizer Files Second Lawsuit to Block Novo Nordisk’s $9bn Metsera Bid
Pfizer alleges Novo Nordisk’s $6 billion bid to acquire Metsera is anticompetitive and aims to block the deal under the Clayton Antitrust Act, citing risks to market competition.
- On Monday, Pfizer filed a second lawsuit in Delaware alleging Novo Nordisk's $9 billion outbid is anticompetitive and accusing Metsera's controlling shareholders of conspiring with both companies.
- After struggling to launch its own obesity products, Pfizer targeted Metsera to acquire two late-stage candidates and agreed in September to pay $4.9 billion, rising to $7.3 billion with future payments.
- Metsera's pipeline includes a GLP‑1 agonist and an amylin analogue ready for phase 3 that could enable once‑monthly dosing versus weekly rivals, with analysts estimating peak annual sales of $5 billion or more.
- Metsera said `Pfizer is trying to litigate its way to buying Metsera for a lower price than Novo Nordisk` and said it will address the filings in court.
- Pfizer alleges the bid would protect Novo Nordisk's dominant GLP‑1 position by sidelining a U.S. rival, warning it would harm millions of Americans with obesity, diabetes, and metabolic conditions.
Insights by Ground AI
14 Articles
14 Articles
Metsera calls Pfizer threats ‘nonsense’ as rift widens between companies
Metsera calls Pfizer threats 'nonsense' as rift widens between companies Pfizer and Novo Nordisk’s battle over obesity biotech Metsera is getting ugly. On Monday, Metsera asked the Delaware Court of Chancery to deny Pfizer’s request …
Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal – RamaOnHealthcare
Pfizer claims Metsera breached their merger agreement, adding that a tie-up of the biotech with GLP-1 drug giant Novo Nordisk would violate U.S. antitrust law. Metsera called the arguments “nonsense” and said Pfizer is trying to buy the obesity drug developer for less than what Novo is willing to pay.Pfizer now has the required regulatory [...]
Coverage Details
Total News Sources14
Leaning Left0Leaning Right0Center4Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
